Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

BENEFICIAL OWNERSHIP

STATEMENT	OF CHANGE	S IN

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* LYONS GARY A						2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [NBIX]							BIX Ch	elationship eck all appli X Directo	cable)	,			
(Last)	`	irst) DSCIENCES, IN	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/19/2006							-	X Officer below)	(give title Presiden	t and	Other (s below)	pecify	
12790 EL CAMINO REAL					_ _	If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable					
(Street)	EGO C.	A	92130		4. II Amerianent, Date of				ongman med (Month Day) real)				Line						
(City)	(S	tate)	(Zip)											1 01301					
		Tab	le I - Nor	ı-Deri\	vativ	e Se	curities	Aco	quired, D	isp	osed o	f, or Be	neficiall	y Owned	ı				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,		Date,	Transaction Dispose Code (Instr. 5)		ities Acquired (A) o d Of (D) (Instr. 3, 4 a		5. Amou Securitie Benefici Owned I Reporte	es ally Following	Form (D) o	m: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code V	·	Amount	(A) or (D)	Price	Transac (Instr. 3	ction(s)			Instr. 4)			
		-	Fable II -						uired, Dis , options					Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,		saction of Deriv Secu Acquired (A) of Disp of (D 3, 4 a)		ve es d	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and of Security Underlying Derivative (Instr. 3 and	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)		Date Exercisable	Ex Da	piration ate	Title	Amount or Number of Shares						
Stock Option ⁽¹⁾	\$60.95	01/19/2006			A		60,000		02/19/2006	01/	/19/2013	Common Stock	60,000	\$60.95	60,00	0	D		
Restricted Stock	(2)	01/19/2006			A		20,000		(3)		(3)	Common Stock	20,000	\$0	20,00	0	D		

Explanation of Responses:

- 1. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 19, 2006 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- 2. Each restricted stock unit represents a contingent right to receive one share of Neurocrine Common Stock.
- 3. The restricted stock units will vest monthly at 1/36th of the units beginning February 19, 2006. Vested shares will be delivered to the reporting person in January following the year in which the reporting person terminates employment with Neurocrine

Remarks:

Margaret E. Valeur-Jensen, By Power of Attorney

01/23/2006

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.